This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Inhalation SLIT Cisplatin for the Treatment of Osteosarcoma Metastatic to the Lung

This study has been completed.
Information provided by:
Insmed Incorporated Identifier:
First received: January 29, 2005
Last updated: July 7, 2010
Last verified: July 2010
Phase Ib/IIa study to determine the safety and efficacy of inhaled SLIT Cisplatin administered every other week to patients with Osteosarcoma who have disease that has spread to the lung.

Condition Intervention Phase
Osteosarcoma Drug: SLIT Cisplatin Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase Ib/IIa Study of SLIT Cisplatin by Inhalation in the Treatment of Patients Wtih Relapsed/Progressive Osteosarcoma Metastatic to the Lung

Resource links provided by NLM:

Further study details as provided by Insmed Incorporated:

Primary Outcome Measures:
  • Safety
  • Response
  • Pharmacokinetics

Secondary Outcome Measures:
  • Duration of response

Estimated Enrollment: 21
Study Start Date: January 2005
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Detailed Description:

Osteosarcoma, preferentially metastasizes to the lung. The presence of lung metastases has a major impact on the prognosis of patients with osteosarcoma. Upon surgical removal of the tumor in the lung, new pulmonary metastases often recur within months suggesting micro-metastatic disease resistant to systemic chemotherapy.

The Sustained release lipid inhalation targeting (SLIT) technology offers the potential ability to attain a prolonged therapeutic effect of cisplatin in the lung by sustained release. The ability to give SLIT Cisplatin by inhalation directly to the lung permits high drug levels at the site of disease with low systemic exposure.

Patients will receive SLIT Cisplatin by inhalation for a 14-day treatment cycle in this phase Ib/IIa, two-center, open-label, study designed to characterize the maximum tolerated dose. Clinical efficacy endpoints will be included and compared to historical controls, in addition to pharmacokinetics characterization. Efficacy will be evaluated after at least 2 cycles of therapy. Safety data, including laboratory parameters and adverse events will be collected to determine the qualitative and quantitative toxicity, and reversibility of toxicity, of SLIT Cisplatin. Pulmonary function tests will be performed at baseline, prior to each course and at off-study.


Ages Eligible for Study:   13 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven, Progressive or recurrent high grade osteosarcoma metastatic to the lung
  • Measureable pulmonary metastases.
  • Less than grade 3 neuropathies, insignificant decreases in cardiac or auditory function
  • ECOG performance status of 0, 1 or 2
  • FEV1 of 50% or greater of predicted value
  • FEV1/FVC ratio of 65% or greater
  • Serum creatinine of </= 1.5 mg/dl
  • Total bilirubin </= 1.5mg/dl and SGOT or SGPT < 2.5 x upper normal limit
  • ANC of >/= 1,000/mm3 and platelet count of >= 100,000/mm3

Exclusion Criteria:

  • Grade 3 or higher neuropathy
  • Concurrent systemic chemotherapy
  • Pulmonary atelectasis
  • Significant reactive airway disease
  • Concurrent serious infections
  • Unstable or serious concurrent medical condition
  • Recent major surgery
  • Significant pulmonary fibrosis
  • Major ventilatory distribution abnormalities
  • Osteosarcoma secondary to radiation or premalignant conditions
  • History of prior malignancy
  • Low grade osteosarcoma, parosteal or periosteal sarcoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00102531

United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
The Albert Einstein College of Medicine Montefiore Medical Center
New York, New York, United States, 10467
Sponsors and Collaborators
Insmed Incorporated
Study Chair: Renu Gupta, MD Transave Inc.
Principal Investigator: Richard Gorlick, MD The Albert Einstein College of Medicine Montefiore Medical Center
  More Information Identifier: NCT00102531     History of Changes
Other Study ID Numbers: TR02-2421
Study First Received: January 29, 2005
Last Updated: July 7, 2010

Keywords provided by Insmed Incorporated:

Additional relevant MeSH terms:
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Antineoplastic Agents processed this record on June 23, 2017